Skip to main content

"Effects of Co-Released Orexin and Dynorphin on Ventral Tegmental Area Dopamine Neuronal Activity and Opioid Seeking" | Stephanie Borgland, Ph.D

Friday, October 4, 2024 | 12:00 PM - 1:00 PM CT
Ward Building, 5-230, 303 E. Chicago Avenue, Chicago, IL 60611 map it

The Department of Neuroscience Welcomes Stephanie Borgland.

Dr. Stephanie Borgland is a Professor and a Tier 1 Canada Research Chair in the Departments of Physiology & Pharmacology as well as Psychiatry at the University of Calgary.

The misuse of opioids and other prescription pain relievers has risen rapidly, becoming a major global health issue. Addiction is linked to neural circuit dysfunction, characterized by changes in synaptic transmission in the ventral tegmental area (VTA), a region involved in the incentive value of drug-related stimuli. The lateral hypothalamic (LH) neuropeptide, orexin (ox; also known as hypocretin), is necessary for the formation of morphine induced plasticity of VTA dopamine neurons. Orexins and dynorphin (dyn) are co-expressed LH neuropeptides that project to VTA. These peptides have opposing effects on the firing activity of VTA dopamine (DA) neurons via orexin 1 (Ox1) or kappa opioid (KOR) receptors, respectively. Therefore, it is unclear how the co-released peptides contribute to the activity of dopamine neurons in physiological and pathological states. This study aimed to determine how chronic morphine alters the contributions of LHox/dyn to the firing of VTA DA neurons. We found that repeated opioid treatment shifts the LHox/dyn regulation of VTA dopamine neurons that project to the BLA from inhibitory to primarily excitatory. This may influence the responsiveness of the mouse to opioid-related cues. 

Audience

  • Faculty/Staff
  • Student
  • Post Docs/Docs
  • Graduate Students

Contact

Jenna Ward   (815) 529-6182

jenna.ward@northwestern.edu

Interest

Add Event To My Group

Please sign-in